P2RY12 and atrial fibrillation: The current evidence from four major randomized controlled trials showed that direct oral anticoagulants (DOACs) plus P2Y12 inhibitors can prevent bleeding complications in patients with atrial fibrillation who receive coronary stent(s) without increasing the risk of stent thromboses.